JPWO2020205875A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020205875A5 JPWO2020205875A5 JP2021560506A JP2021560506A JPWO2020205875A5 JP WO2020205875 A5 JPWO2020205875 A5 JP WO2020205875A5 JP 2021560506 A JP2021560506 A JP 2021560506A JP 2021560506 A JP2021560506 A JP 2021560506A JP WO2020205875 A5 JPWO2020205875 A5 JP WO2020205875A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- binding
- heavy chain
- domain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091008324 binding proteins Proteins 0.000 claims description 23
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 17
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 17
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 10
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 10
- 102000014909 interleukin-1 receptor activity proteins Human genes 0.000 claims description 10
- 108040006732 interleukin-1 receptor activity proteins Proteins 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 102000023732 binding proteins Human genes 0.000 claims 22
- 102000010932 Interleukin-1 receptor type 1 Human genes 0.000 claims 3
- 108050001109 Interleukin-1 receptor type 1 Proteins 0.000 claims 3
- 230000004913 activation Effects 0.000 claims 3
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 claims 2
- 102000003777 Interleukin-1 beta Human genes 0.000 claims 2
- 108090000193 Interleukin-1 beta Proteins 0.000 claims 2
- 102100026017 Interleukin-1 receptor type 2 Human genes 0.000 claims 2
- 101710149731 Interleukin-1 receptor type 2 Proteins 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 101100174574 Mus musculus Pikfyve gene Proteins 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 43
- 238000003556 assay Methods 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 230000012846 protein folding Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 229950002916 avelumab Drugs 0.000 description 1
- 229960001838 canakinumab Drugs 0.000 description 1
- 229940121420 cemiplimab Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229950009791 durvalumab Drugs 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- DDDQVDIPBFGVIG-UHFFFAOYSA-N plafibride Chemical compound C1COCCN1CNC(=O)NC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 DDDQVDIPBFGVIG-UHFFFAOYSA-N 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
Images
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962827381P | 2019-04-01 | 2019-04-01 | |
| US62/827,381 | 2019-04-01 | ||
| PCT/US2020/025979 WO2020205875A1 (en) | 2019-04-01 | 2020-03-31 | Bispecific binding molecules that target the tumor microenvironment and an immune checkpoint protein |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022525238A JP2022525238A (ja) | 2022-05-11 |
| JP2022525238A5 JP2022525238A5 (https=) | 2024-02-28 |
| JPWO2020205875A5 true JPWO2020205875A5 (https=) | 2024-02-28 |
Family
ID=72607367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021560506A Pending JP2022525238A (ja) | 2019-04-01 | 2020-03-31 | 腫瘍微小環境および免疫チェックポイントタンパク質を標的とする二重特異性結合分子 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11718673B2 (https=) |
| EP (1) | EP3947449A4 (https=) |
| JP (1) | JP2022525238A (https=) |
| KR (1) | KR20220004067A (https=) |
| CN (1) | CN114127107B (https=) |
| AU (1) | AU2020252191A1 (https=) |
| CA (1) | CA3135838A1 (https=) |
| TW (1) | TW202102539A (https=) |
| WO (1) | WO2020205875A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021231773A1 (en) | 2020-05-13 | 2021-11-18 | Good Therapeutics, Inc. | Compositions of protein complexes and methods of use thereof |
| CA3201518A1 (en) * | 2020-11-18 | 2022-05-27 | Suzhou Transcenta Therapeutics Co., Ltd. | Bi-functional molecules |
| CN121511262A (zh) * | 2023-06-28 | 2026-02-10 | 北京哲源科技有限责任公司 | 靶向pd-l1和il-1的双特异性抗体及其用途 |
| WO2025119346A1 (en) * | 2023-12-07 | 2025-06-12 | LaNova Medicines Limited | Anp-dependent antibodies |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2714738B1 (en) * | 2011-05-24 | 2018-10-10 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
| AU2014227638A1 (en) * | 2013-03-15 | 2015-09-17 | Merck Patent Gmbh | Tetravalent bispecific antibodies |
| WO2015035365A1 (en) * | 2013-09-09 | 2015-03-12 | The Nohns Hopkins University | Targeting the m2-tumor associated macrophage for cancer therapy |
| WO2016141387A1 (en) * | 2015-03-05 | 2016-09-09 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| EA201890790A1 (ru) * | 2015-09-29 | 2018-10-31 | Селджин Корпорейшн | Связывающие pd-1 белки и способы их применения |
| AR108377A1 (es) * | 2016-05-06 | 2018-08-15 | Medimmune Llc | Proteínas de unión biespecíficas y sus usos |
| WO2018049261A1 (en) * | 2016-09-09 | 2018-03-15 | Icellhealth Consulting Llc | Oncolytic virus expressing immune checkpoint modulators |
| WO2018119001A1 (en) | 2016-12-19 | 2018-06-28 | Fred Hutchinson Cancer Research Center | Peptide-antibody compositions and methods of use thereof |
| JP2020524694A (ja) * | 2017-06-22 | 2020-08-20 | ノバルティス アーゲー | がんの処置における使用のためのＩＬ−１β結合性抗体 |
| WO2018235056A1 (en) * | 2017-06-22 | 2018-12-27 | Novartis Ag | Il-1beta binding antibodies for use in treating cancer |
-
2020
- 2020-03-31 CN CN202080034654.XA patent/CN114127107B/zh active Active
- 2020-03-31 TW TW109110936A patent/TW202102539A/zh unknown
- 2020-03-31 CA CA3135838A patent/CA3135838A1/en active Pending
- 2020-03-31 JP JP2021560506A patent/JP2022525238A/ja active Pending
- 2020-03-31 KR KR1020217035631A patent/KR20220004067A/ko not_active Ceased
- 2020-03-31 WO PCT/US2020/025979 patent/WO2020205875A1/en not_active Ceased
- 2020-03-31 AU AU2020252191A patent/AU2020252191A1/en not_active Abandoned
- 2020-03-31 EP EP20784051.3A patent/EP3947449A4/en not_active Withdrawn
- 2020-03-31 US US16/836,197 patent/US11718673B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sedykh et al. | Bispecific antibodies: design, therapy, perspectives | |
| Kriangkum et al. | Bispecific and bifunctional single chain recombinant antibodies | |
| US11987635B2 (en) | Anti-4-1BB antibodies and methods of making and using thereof | |
| JP2020048564A5 (https=) | ||
| JP2020520665A5 (https=) | ||
| US20040220388A1 (en) | Novel heterodimeric fusion proteins | |
| JP2009517006A5 (https=) | ||
| TW201803899A (zh) | 三特異性和／或三價結合蛋白 | |
| JP2019525771A5 (https=) | ||
| JP2018537966A5 (https=) | ||
| KR102627471B1 (ko) | 조작된 항-il-2 항체 | |
| JP2018533371A5 (https=) | ||
| JPH07504808A (ja) | Ｃｄｒをグラフトしたヒト化キメラｔ細胞抗体 | |
| JP2017505121A5 (https=) | ||
| CN118063619A (zh) | 工程化的异源二聚体蛋白质 | |
| CA2487060A1 (en) | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency | |
| CN115335405A (zh) | 全人源抗人cd22的嵌合抗原受体及其应用 | |
| JP2021524451A5 (https=) | ||
| JPWO2020252366A5 (https=) | ||
| JPH05503687A (ja) | 自己免疫疾患の治療 | |
| CN115746144B (zh) | 抗tigit-pd1双特异性抗体及其应用 | |
| JPWO2020205875A5 (https=) | ||
| IL277899B1 (en) | Methods and compositions for treating yellow fever | |
| CN121039162A (zh) | 靶向g蛋白偶联受体的双特异性抗体 | |
| JPWO2023056252A5 (https=) |